Skip to content

Clinical and Neuropsychological Investigations in Batten Disease

Clinical and Neuropsychological Investigations in Batten Disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01873924
Enrollment
500
Registered
2013-06-10
Start date
2004-08-31
Completion date
2035-08-31
Last updated
2025-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Batten Disease, Neuronal Ceroid Lipofuscinosis, Neuronal Ceroid Lipofuscinosis CLN1, Neuronal Ceroid Lipofuscinosis CLN10, Neuronal Ceroid Lipofuscinosis CLN2, Neuronal Ceroid Lipofuscinosis CLN3, Neuronal Ceroid Lipofuscinosis CLN5, Neuronal Ceroid Lipofuscinosis CLN6, Neuronal Ceroid Lipofuscinosis CLN7, Neuronal Ceroid Lipofuscinosis CLN8

Keywords

Batten disease, NCL, Neuronal Ceroid Lipofuscinosis

Brief summary

This study aims to assess the natural history of Batten disease (Neuronal Ceroid Lipofuscinosis) by obtaining information about the motor, behavioral, and functional capabilities of individuals with Batten disease. This study will also refine and validate the Unified Batten Disease Rating Scale (UBDRS) as a clinical rating instrument for Batten disease.

Detailed description

Batten Disease is an inherited disorder that causes progressive cognitive and behavioral decline in children. There have been no systematic clinical studies of Batten Disease using standardized rating instruments with known inter-rater reliability and validity. The Batten Study Group developed the Unified Batten Disease Rating Scale (UBDRS), a clinical rating instrument used to assess the motor, behavioral, and functional capabilities of individuals with Batten disease. Using the UBDRS, study investigators will evaluate participants approximately every year to track disease progression. The UBDRS is the primary natural history tool, but the study also includes neuropsychological assessment, adaptive function, quality of life measures, and other measures to assess the impact of Batten Disease. Participants will be examined at the University of Rochester Batten Center, Batten Disease Support and Research Association annual meeting, or remotely via televideo. Information related to racial and ethnic background, medical history, symptoms, medications, and diagnostic testing will be collected.

Interventions

None listed

Sponsors

University of Rochester
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* child or adult with any form of Batten disease * parent or legal guardian of a child or adult with any form of Batten disease

Exclusion criteria

\- parent or guardian unable or unwilling to provide permission for the affected individual

Design outcomes

Primary

MeasureTime frameDescription
Unified Batten Disease Rating Scale (UBDRS), assessing the severity and change in physical, seizure, behavioral, and functional aspects of individuals with Batten Disease.Annual Assessments for up to 20 yearsA quantitative measure of natural history

Secondary

MeasureTime frameDescription
Cognitive and neurobehavioral functioning of individuals with Batten diseaseAnnual Assessments for up to 10 yearsA standardized battery of neuropsychological tests and neurobehavioral assessments will be used to measure cognitive skills (e.g., verbal reasoning, attention, memory, language), mood, behavior, adaptive function, and quality of life.
Quantitative assessment of vision and retinal thicknessAnnual Assessments for up to 20 yearsVision and retinal thickness assessments include visual acuity, visual fields, fundus photography to document anatomic extent of disease, fundus autofluorescence to measure lipofuscin accumulation, and optical coherence tomography (OCT) to provide detailed images of retinal structure, measure retinal layers, and measure central macular thickness.

Countries

United States

Contacts

Primary ContactAmy Vierhile, RN PNP
amy_vierhile@urmc.rochester.edu(585)275-4762

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026